Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease

被引:0
|
作者
Bodini, G. [1 ]
Del Nero, L. [1 ]
Giannini, E. G. [1 ]
Tolone, S. [2 ]
De Bortoli, N. [3 ]
Anjali, J. [4 ]
Baldissarro, I. [1 ]
Savarino, V. [1 ]
Savarino, E. [5 ]
机构
[1] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy
[2] Univ Naples 2, Dept Surg, Naples, Italy
[3] Univ Pisa, Dept Internal Med, Gastroenterol Unit, Pisa, Italy
[4] Prometheus Labs, Dept Res & Dev, San Diego, CA USA
[5] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, Padua, Italy
来源
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P607
引用
收藏
页码:S408 / S409
页数:2
相关论文
共 50 条
  • [31] Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment
    Patil, Abhishek
    Upadhyaya, Sundeep
    Dawar, Reetika
    Dadhaniya, Nikunjkumar
    Sood, Isha
    Gupta, Sirinder J.
    Handa, Rohini
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1638 - 1643
  • [32] Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
    Swaminath, A.
    Ullman, T.
    Rosen, M.
    Mayer, L.
    Lichtiger, S.
    Abreu, M. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 273 - 278
  • [33] Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
    Singh, Namita
    Rosenthal, Casey J.
    Melmed, Gil Y.
    Mirocha, James
    Farrior, Sharmayne
    Callejas, Silvia
    Tripuraneni, Bhavna
    Rabizadeh, Shervin
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1708 - 1713
  • [34] Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease
    Zitomersky, Naamah
    Chi, Lisa
    Liu, Enju
    Bray, Kurtis R.
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    Snapper, Scott B.
    Bousvaros, Athos
    Silvester, Jocelyn A.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 78 (02): : 261 - 271
  • [35] The temporal evolution of anti-drug antibodies in IBD patients treated with infliximab
    Ben-Horin, Shomron
    Ungar, Bella
    Chowers, Yehuda
    Yavzori, Miri
    Picard, Orit
    Fudim, Ella
    Eliakim, Rami
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 145 - 145
  • [36] Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
    Doherty, J.
    Varley, R.
    Healy, M.
    Dunne, C.
    Mac Carthy, F.
    McKiernan, S.
    Hartery, K.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S415 - S416
  • [37] ANTI-DRUG ANTIBODIES DETECTED IN THE PRESENCE OF ADEQUATE INFLIXIMAB DRUG LEVELS IN IBD PATIENTS IN CLINICAL REMISSION HAVE LIMITED CLINICAL SIGNIFICANCE
    Doherty, Jayne
    Varley, Rachel
    Healy, Martin
    Dunne, Cara
    Maccarthy, Finbar
    Mckiernan, Susan
    Hartery, Karen
    Kevans, David
    GASTROENTEROLOGY, 2021, 160 (06) : S692 - S692
  • [38] Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
    Orfanoudaki, E.
    Gazouli, M.
    Foteinogiannopoulou, K.
    Theodouraki, E.
    Legaki, E.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S330 - S331
  • [39] Infliximab Dosing for Patients With Inflammatory Bowel Disease, Based on Trough Levels
    Lowe, Anson W.
    Moseley, Richard H.
    GASTROENTEROLOGY, 2015, 148 (07) : 1261 - 1261
  • [40] INFLIXIMAB TROUGH LEVELS AFTER INDUCTION THERAPY: A PREDICTIVE FACTOR FOR OUTCOME IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    van Hoeve, Karen
    Hoffman, Ilse
    Dreesen, Erwin
    Ferrante, Marc
    Ann, Gils
    Vermeire, Severine
    GASTROENTEROLOGY, 2018, 154 (06) : S1042 - S1043